News | Heart Valve Technology | November 10, 2016

Henry Ford Hospital Cardiologist Performs Pioneering Laser Mitral Valve Treatment

LAMPOON procedure provides option for patients needing mitral valve replacement who are not eligible for open-heart surgery or transcatheter replacement

Greenbaum, Henry Ford Hospital, LAMPOON procedure, mitral valve

November 10, 2016 — A Henry Ford Hospital cardiologist is pioneering a promising new procedure to improve the success of mitral valve replacement.

Interventional cardiologist Adam Greenbaum, M.D., medical co-director of the Center For Structural Heart Disease at Henry Ford Hospital, believes the procedure — slicing a leaflet with an electrified wire through a tiny catheter before replacing a mitral valve — will save thousands of lives.

Greenbaum helped perform the first procedure in man on May 25, 2016 at Emory University in Atlanta and led the second procedure at Henry Ford Hospital on June 8. Since then, cardiologists have performed nine of the highly specialized procedures, six at Henry Ford Hospital.

“It’s in its infancy, but was successful in all patients,” said Greenbaum. “It’s extremely invigorating to say someone who had no options now has a beautifully working mitral valve, repaired in a safe manner with the use of only catheters. This could be life-saving for many people.”

The procedure is medically described as ‘laceration of the anterior mitral valve leaflet to prevent outflow track obstruction,’ and nicknamed with the acronym “LAMPOON.”

The LAMPOON procedure is designed for patients who need a new mitral valve. The mitral valve regulates the flow of blood between the left top and bottom chambers of the heart after it has been oxygenated in the lungs. The ventricle then squeezes the blood out through the aortic valve and into the body.

Doctors can replace a mitral valve two ways: through open-heart surgery, or by deploying a valve through a small catheter guided through blood vessels and into the heart if patients are felt to be too sick for open surgical repairs. But in up to 50 percent of patients, the heart’s anatomy can cause problems. In some people, when the cardiologist positions and opens the new mitral valve, the  original valve leaflet gets pushed back and can block blood flow out of the heart. The complication is fatal.

In open-heart surgery, doctors cut away the blocking tissues. That is not an option for those too sick to undergo open-heart surgery, leading Greenbaum and his team to search for an alternative.

In the catheter-based LAMPOON procedure,  the cardiologist weaves a catheter through the patient’s blood vessels and into the heart. The doctor then uses an electrified wire about the size of a sewing thread woven through the catheter to slice away the problem tissue.

“We don’t know how many people have been turned away due to their anatomic risk,” said Greenbaum. “Now we think we have conquered that obstacle.”

Greenbaum has been working with interventional cardiologist Robert J. Lederman, M.D., and fellow Jaffar Khan, M.D., at the National Heart, Lung, and Blood Institute, who first performed the technique in animals; and Vasilis C. Babaliaros at Emory University School of Medicine, who performed the first human procedure in May.

Greenbaum and Lederman also performed the first transcaval access procedure in man, a novel way to access the heart by connecting blood vessels in the abdomen. A multi-center study of the procedure recently reported a 98 percent success rate for the procedure.

For more information: www.henryfordhospital.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Overlay Init